Cargando…
Treatment strategy for reducing the risk of rituximab-induced cytokine release syndrome in patients with intravascular large B-cell lymphoma: a case report and review of the literature
INTRODUCTION: Intravascular large B-cell lymphoma is a rare aggressive disseminated disease characterized by the presence of lymphoma cells in small vessels without lymphadenopathy. Rituximab, a novel monoclonal antibody against the CD20 B-cell antigen, has been reported to be effective in treating...
Autores principales: | Makino, Katsuhiro, Nakata, Jumi, Kawachi, Satoru, Hayashi, Tatsuyuki, Nakajima, Atsuo, Yokoyama, Munehiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3923559/ https://www.ncbi.nlm.nih.gov/pubmed/24377366 http://dx.doi.org/10.1186/1752-1947-7-280 |
Ejemplares similares
-
Rituximab and Cytokine Release Syndrome
por: Kulkarni, Hrishikesh S., et al.
Publicado: (2012) -
Rituximab-Induced Splenic Rupture and Cytokine Release
por: Nair, Ranjit, et al.
Publicado: (2016) -
Intravascular Large B-Cell Lymphoma
por: Loukhnati, Mehdi, et al.
Publicado: (2023) -
Relapsed intravascular large B-cell lymphoma
por: Jo, Kyoung Il, et al.
Publicado: (2013) -
Intravascular Large B-Cell Lymphoma of the Gallbladder
por: Çetin, Bülent, et al.
Publicado: (2018)